K
Kunzer Aaron R
Researcher at AbbVie
Publications - 52
Citations - 4956
Kunzer Aaron R is an academic researcher from AbbVie. The author has contributed to research in topics: Cancer & Apoptosis. The author has an hindex of 17, co-authored 52 publications receiving 4708 citations. Previous affiliations of Kunzer Aaron R include Idun Pharmaceuticals & Walter and Eliza Hall Institute of Medical Research.
Papers
More filters
Journal ArticleDOI
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf,Steven W. Elmore,Alexander R. Shoemaker,Robert C. Armstrong,David J. Augeri,Barbara A. Belli,Milan Bruncko,Thomas L. Deckwerth,Jürgen Dinges,Philip J. Hajduk,Mary K. Joseph,Shinichi Kitada,Stanley J. Korsmeyer,Stanley J. Korsmeyer,Kunzer Aaron R,Anthony Letai,Chi Li,Michael J. Mitten,David G. Nettesheim,Shi Chung Ng,Paul Nimmer,Jacqueline M. O'Connor,Anatol Oleksijew,Andrew M. Petros,John C. Reed,Wang Shen,Stephen K. Tahir,Craig B. Thompson,Kevin J. Tomaselli,Baole Wang,Wendt Michael D,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg +33 more
TL;DR: Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation.
Journal ArticleDOI
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
Cheol-Min Park,Milan Bruncko,Jessica Adickes,Joy Bauch,Hong Ding,Kunzer Aaron R,Kennan C. Marsh,Paul Nimmer,Alexander R. Shoemaker,Xiaohong Song,Stephen K. Tahir,Christin Tse,Wang Xilu,Michael D. Wendt,Xiufen Yang,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +18 more
TL;DR: Targeted modifications at three key positions of 1 resulted in a 20-fold improvement in the pharmacokinetic/pharmacodynamic relationship (PK/PD) between oral exposure (AUC) and in vitro efficacy in human tumor cell lines (EC 50).
Journal ArticleDOI
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Milan Bruncko,Thorsten Oost,Barbara A. Belli,Hong Ding,Mary K. Joseph,Kunzer Aaron R,Darlene Martineau,Mcclellan William J,Michael J. Mitten,Shi-Chu Ng ng,Paul Nimmer,Tilman Oltersdorf,Cheol-Min Park,Andrew M. Petros,Alexander R. Shoemaker,Xiaohong Song,Wang Xilu,Wendt Michael D,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +21 more
TL;DR: Compound 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.
Patent
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Milan Bruncko,Hong Ding,George A. Doherty,Steven W. Elmore,Lisa A. Hasvold,Laura Hexamer,Kunzer Aaron R,Xiaohong Song,Andrew J. Souers,Gerard M. Sullivan,Zhi-Fu Tao,Wang Gary T,Le Wang,Xilu Wang,Michael D. Wendt,Robert A. Mantei,Todd M. Hansen +16 more
TL;DR: In this paper, compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-APOPotic BCL-2 protein.
Journal ArticleDOI
Discovery and Structure−Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotentiation Activity in Vitro and in Vivo
Wendt Michael D,Wang Shen,Kunzer Aaron R,Mcclellan William J,Milan Bruncko,Thorsten Oost,Hong Ding,Mary K. Joseph,Haichao Zhang,Paul Nimmer,Shi-Chung Ng,Alexander R. Shoemaker,Andrew M. Petros,Anatol Oleksijew,Kennan C. Marsh,Joy Bauch,Tilman Oltersdorf,Barbara A. Belli,Darlene Martineau,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +21 more
TL;DR: Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-X(L) function, 73R, potentiates the activity of paclitaxel and UV irradiation in vitro and potentiated the antitumor efficacy of pac litaxel in a mouse xenograft model.